Search results
Showing 226 to 240 of 1094 results for infections
Recommendation ID NG25/2 Question Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the...
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
although these don't always work. Infections, including wound infections, vaginal infections and urinary tract...
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (HTG300)
Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.
View recommendations for HTG300Show all sections
Sections for HTG300
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.
could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment? Any...
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.
This indicator covers the percentage of children who reached 18 months old in the preceding 12 months, who have received 2 primary doses and 1 booster dose of a meningitis B vaccine before the age of 18 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
This indicator the percentage of babies who reached 8 months old in the preceding 12 months, who have received 2 doses of a meningitis B vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM207
This indicator covers the percentage of babies who reached 24 weeks old in the preceding 12 months, who have received 2 doses of rotavirus vaccine before the age of 24 weeks. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM206
This indicator covers the percentage of children who reached 5 years old in the preceding 12 months, who have received 1 dose of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM200
This indicator covers the percentage of children who have reached 5 years old in the preceding 12 months, who have received a reinforcing dose of DTaP/IPV and at least 2 doses of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM199